^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Solucin (177Lu-edotreotide)
i
Other names: 177Lu-DOTATOC, ITM-11, n.c.a. 177Lu-edotreotide, 177Lu-Edo, ITM11, ITM 11
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
China Grand Pharma, ITM Isotopen Technologien Munchen
Drug class:
Beta radiation emitter, SSTR2 inhibitor
Related drugs:
6d
LEVEL: Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (clinicaltrials.gov)
P3, N=170, Recruiting, Grupo Espanol de Tumores Neuroendocrinos | N=120 --> 170 | Trial completion date: Jul 2028 --> Oct 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
Enrollment change • Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
everolimus • Solucin (177Lu-edotreotide)
2ms
ITM11 Expanded Access Program (clinicaltrials.gov)
P=N/A, N=0, Available, ITM Solucin GmbH
New trial
|
Solucin (177Lu-edotreotide)
5ms
KinLET: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
P1, N=20, Recruiting, ITM Solucin GmbH | Not yet recruiting --> Recruiting
Enrollment open
|
Solucin (177Lu-edotreotide)
6ms
Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors. (PubMed, J Neuroendocrinol)
Overall, these findings suggest that the efficacy and safety of [177Lu]Lu-edotreotide are in line with those reported for other RPTs in similar clinical settings. Clinical Trial Registration: PROSPERO 2024 CRD42024518028.
Retrospective data • Review • Journal
|
SSTR (Somatostatin Receptor)
|
Solucin (177Lu-edotreotide)
8ms
START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
P3, N=300, Recruiting, Lund University Hospital | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
capecitabine • Solucin (177Lu-edotreotide)
12ms
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov)
P3, N=259, Active, not recruiting, ITM Solucin GmbH | Recruiting --> Active, not recruiting
Enrollment closed
|
SSTR (Somatostatin Receptor)
|
SSTR positive
|
5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
1year
PROMENADE: Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (clinicaltrials.gov)
P1/2, N=18, Recruiting, University Hospital, Basel, Switzerland | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Phase classification • Trial completion date • Trial primary completion date
|
SSTR (Somatostatin Receptor)
|
SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)
1year
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). (PubMed, BMC Cancer)
The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.
Clinical • Clinical protocol • Journal • HEOR
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
everolimus • Solucin (177Lu-edotreotide)
over1year
KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Sep 2024 --> Jan 2025
Trial initiation date
|
Solucin (177Lu-edotreotide)
over1year
KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Jun 2024 --> Sep 2024
Trial initiation date
|
Solucin (177Lu-edotreotide)
over1year
START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
P3, N=300, Recruiting, Lund University Hospital | Active, not recruiting --> Recruiting
Enrollment open
|
SSTR (Somatostatin Receptor)
|
capecitabine • Solucin (177Lu-edotreotide)
almost2years
LUFOR: "Receptor Radionuclide Therapy With 177Lu-DOTATOC (clinicaltrials.gov)
P2, N=100, Recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Not yet recruiting --> Recruiting
Enrollment open
|
SSTR2 (Somatostatin Receptor 2)
|
Solucin (177Lu-edotreotide)
Share via
